Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

TCM (570 HK): Sinopharm's $4.60/Share Offer

Trad Chi Med (570 HK): Sinopharm's Feverish Proposal

Quiddity Advisors

Event-Driven

China Traditional Chinese Medicine / Event-Driven

China Traditional Chinese Medicine (570 HK)

<ul>
<li>
<strong><a href="https://www.smartkarma.com/entities/china-traditional-chinese-medicine" target="_blank" data-smartkarma-citation="entities:351:1" rel="noopener">China Traditional Chinese Medicine (570 HK)</a></strong> ("TCM") is the traditional Chinese medicine arm of SASAC-managed China National Pharmaceutical Group Corporation (CNPGC), one of the largest healthcare groups in China.</li>
<li>By my reckoning, TCM has fielded three Offers in the past decade, all from Sinopharm Hongkong, an indirect wholly-owned subsidiary of CNPGC and TCM’s major shareholder.</li>
<li>TCM was <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0208/2024020800189.pdf" target="_blank" rel="noopener">suspended</a> "pursuant to the Code on Takeovers and Mergers" earlier today. The Real McCoy? A no-deal again from CNPGC/Sinopharm? And why didn't the last Offers complete?</li>
</ul>



China Traditional Chinese Medicine (570 HK) ("TCM") is the traditional Chinese medicine arm of SASAC-managed China National Pharmaceutical Group Corporation (CNPGC), one of the largest healthcare groups in China.
By my reckoning, TCM has fielded three Offers in the past decade, all from Sinopharm Hongkong, an indirect wholly-owned subsidiary of CNPGC and TCM’s major shareholder.
TCM was suspended "pursuant to the Code on Takeovers and Mergers" earlier today. The Real McCoy? A no-deal again from CNPGC/Sinopharm? And why didn't the last Offers complete?


China Traditional Chinese Medicine

TCM (570 HK): We've Been Here Before